Okogen is a specialized pharmaceutical company in the field of ophthalmology, with a focus on creating innovative treatments for adenoviral conjunctivitis. Our emphasis is on addressing the root cause of the condition as well as managing its related symptoms. The primary product candidate, OKG-0502, is in development for the treatment of adenoviral conjunctivitis, also referred to as pink eye. This viral infection impacts an estimated 30 million individuals globally annually and currently lacks approved therapies.